Kylie Yang

Kylie Yang

Auto-generated profile, based on publicly available information

Kylie Yang

Chemistry Department, UCL, 20 Gordon Street, London WC1H 0AJ, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 September 2021 in Organic & Biomolecular Chemistry
Verified
Journal Article
Closed access
PDF file
JLJiarun Lin
Jiarun Lin
KYKylie Yang
Kylie Yang
Elizabeth NewElizabeth New
Elizabeth New
Here we provide a comprehensive review of methods for targeting fluorescent cargo to sub-cellular organelles.

29 September 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
KYKylie Yang
Kylie Yang
JBJessica E. Boles
Jessica E. Boles
Lisa Jane WhiteLisa Jane White
Lisa Jane White
KHKira L. F. Hilton
Kira L. F. Hilton
HLHin Yuk Lai
Hin Yuk Lai
CHCally Haynes
Cally Haynes
Synthetic ionophores are promising therapeutic targets, yet poor water solubility limits their potential for translation into the clinic. Here we report a water soluble, supramolecular self-associating amphiphile (SSA) with cation transport function.

3 February 2025 in Chemistry–Methods
Verified
Journal Article
Open access
KYKylie Yang
Kylie Yang
LLLana C. Lee
Lana C. Lee
HKHiral A. Kotak
Hiral A. Kotak
EMEvelyn R. Morton
Evelyn R. Morton
SCSoo Mei Chee
Soo Mei Chee
CHCally Haynes
Cally Haynes
Ion transport across biological lipid membranes is crucial for both health and disease, prompting investigation into synthetic ion transporters as potential therapeutics. However, state of the art methods for assessing transporter activity are often time‐consuming and resource‐intensive, hindering the screening of large compound libraries. In this work we have developed an automated high‐throughput assay capable of determining 24 EC50 values in a single day. This assay, adapted from the established lucigenin Cl−/NO3− antiport method, has been optimised for multi‐well plates with fully automated liquid handling. Notably, our protocol allows for the use of DMSO as a delivery solvent for target molecules, enhancing its versatility. Validation with six standard ion transporters demonstrated a strong correlation between the EC50 values obtained through our assay and previously reported values, confirming its efficacy and potential for broader applications in the field of ion transport.

3 March 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
KYKylie Yang
Kylie Yang
CMCaleb Marsh
Caleb Marsh
LWLisa J. White
Lisa J. White
FMFergus W. Molyneux
Fergus W. Molyneux
TAThomas L. Allam
Thomas L. Allam
CHCally Haynes
Cally Haynes
Small molecule ion transporters have shown promise as potential therapeutics for microbial infections, cancer and channelopathies. However, there are still gaps in our understanding of how ion transport function in model vesicle membranes translates to cell membranes of interest. The lipid composition of the membranes of bacterial and cancer cells differs markedly from normal human cells, yet the influence of the lipid composition on membrane function is rarely investigated – in part because of the low throughput and high cost of ion transport experiments. Here, we report an increased throughput Workflow to identify biologically relevant, pH-driven ion transport and membrane lysis pathways in vesicle membranes. We developed a set of four assays designed to report on different transport and lysis processes. We validated our assays against a panel of known transporters and produced a stepwise Workflow for the evaluation of libraries of compounds. We applied our Workflow to screen a library (Library 1) of 31 supramolecular, self-associating amphiphiles (SSAs) for transport and lysis activity in a range of vesicles with different lipid compositions, designed to mimic different types of cells, and consequently identified seven promising transporters. Antimicrobial experiments found that six of these promising transporters showed good antimicrobial activity against clinically relevant Staphylococcus aureus strains, highlighting the promise of our Workflow in identifying potential antimicrobial agents. We then applied our Workflow to investigate the ion transport and lysis properties of a second library (Library 2) of SSAs with established antimicrobial and anticancer properties, aiming to provide insight into the biological modes of action.

10 March 2026 in Chemical Science
Verified
Journal Article
Open access
PDF file
PPPrecious I. A. Popoola
Precious I. A. Popoola
TAThomas L. Allam
Thomas L. Allam
RLRebecca J. Lilley
Rebecca J. Lilley
CMChandni Manwani
Chandni Manwani
OKOlivia B. Keers
Olivia B. Keers
Jennifer HiscockJennifer Hiscock
Jennifer Hiscock
Novel amphiphiles target cell membranes, demonstrating biological efficacy against resistant S. aureus and ovarian cancer, with strong mechanistic and DMPK evidence for future therapeutic development.

5 March 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
PPPrecious Popoola
Precious Popoola
TAThomas Allam
Thomas Allam
RLRebecca Lilley
Rebecca Lilley
CMChandni Manwani
Chandni Manwani
OKOlivia Keers
Olivia Keers
Jennifer HiscockJennifer Hiscock
Jennifer Hiscock
Differences in the lipid composition of prokaryotic and eukaryotic cell membranes are well understood and can be exploited to produce novel antimicrobials. However, what is less well recognised is that alteration in the phospholipid composition of the cell membrane is also one of the first phenotypic changes when a cell becomes cancerous. In addition, changes in phospholipid cell membrane composition are a known cause of drug resistance in both microbial disease and cancer. Here we present a series of chiral, amino acid appended supramolecular self-associating amphiphiles that suggest membrane active technologies can be used to simultaneously produce novel drugs in the fight against two of the greatest global health threats facing us today, antimicrobial resistant infections and cancer diseases. We demonstrate the antimicrobial and anticancer efficacy of this membrane active amphiphile technology against susceptible and resistant Staphylococcus aureus and ovarian cancer cells. We hypothesise a mode of action, building on a previous body of evidence, through a combination of vesicle, NMR spectroscopy and patch clamp experiments. We also provide evidence that supports the potential for this class of compound to be developed as pharmaceutical agents against these diseases through in vitro drug metabolism and pharmacokinetics experiments alongside in vivo Galleria mellonella toxicity experiments.